Evaluation of the pharmacotherapeutic follow-up effectiveness in patients with dyslipidemia in the secondary health care in the Brazilian Unified Health System (SUS)
Título del documento: Evaluation of the pharmacotherapeutic follow-up effectiveness in patients with dyslipidemia in the secondary health care in the Brazilian Unified Health System (SUS)
Revista: Brazilian Journal of Pharmaceutical Sciences
Base de datos: PERIÓDICA
Número de sistema: 000451715
ISSN: 1984-8250
Autores: 1
2
3
4
1
Instituciones: 1Universidade Estadual de Maringa, Departamento de Farmacia, Maringa, Parana. Brasil
2Universidade Estadual do Parana, Colegio de Matematicas, Paranavai, Parana. Brasil
3Universidade Estadual de Ponta Grossa, Departamento de Medicina, Ponta Grossa, Parana. Brasil
4Universidade Estadual de Londrina, Departamento de Ciencias Farmaceuticas, Londrina, Parana. Brasil
Año:
Volumen: 58
País: Brasil
Idioma: Inglés
Tipo de documento: Artículo
Enfoque: Analítico, descriptivo
Resumen en inglés Cardiovascular diseases (CVD) are one of the main causes of mortality in the world. Dyslipidemia treatment can reduce the number of deaths caused by CVD, by decreasing the lipid profile. Evaluate the pharmacotherapeutic follow-up effectiveness in patients with dyslipidemia, regarding clinical and laboratory aspects. A quasi-experimental trial was performed in 12 months. The studied population was included patients with dyslipidemia who received a pharmacotherapeutic follow-up, which was evaluated according to the Pharmacotherapy Workup developed by the Brazilian Ministry of Health. Clinical and laboratory evaluations were performed at the baseline, after a 6 and 12-months period. The statistical analyzes were performed with the normality test of Lilliefors, Cramer Von Misses, and Anderson Darling, later the t-paired test. This study demonstrated that after 6-months of intervention, statistically significant results were verified in the reduction of LDL-cholesterol, total cholesterol, increase in HDL-cholesterol, and reduction in the blood pressure. It was observed that for high-risk patients, the achievement of targets in the lipid profile and HbA1C occurred only after 12-months, because, this population needs more aggressive targets and expressive interventions. Pharmacotherapeutic follow-up in patients with dyslipidemia reduced lipid blood levels and promoted positive clinical and laboratory outcomes
Disciplinas: Medicina
Palabras clave: Farmacología,
Farmacoterapia,
Anticolesterolemiantes,
Dislipidemia
Keyword: Pharmacology,
Pharmacotherapy,
Dyslipidemia,
Anticholesteremic agents
Texto completo: Texto completo (Ver HTML) Texto completo (Ver PDF)